Hormuz risk pushes Hunt’s oil call toward $80 (not $90–100), the team hunts for value on a high market — and lands on hyperscaler infrastructure over AI models — while healthcare delivers the first MRD-guided cancer approval and a live UNH margin-recovery setup.
The Cashflow Memo
Key Takeaways
* Hunt on Hormuz: a multi-week/month US–Iran stalemate keeps crude closer to $80 than $65 (not $90–100); producers still budget off the 2027 strip, so higher spot just widens backwardation rather than spurring rig activity.
* Value on page one of the memo: Amazon, Microsoft (~20x earnings), and Google/Alphabet (~30x) look reasonable once hyperscaler CapEx is treated as optional and data-center replacement cost is priced as a real asset; Jason argues models are commoditizing and the durable value is token infrastructure (Amazon Trainium + hosting overlooked).
* Oracle near a 52-week low after the OpenAI capacity commitment and ~$110B net debt looks more value trap than bargain; IBM’s mainframe weakness this week is a signal that legacy IT budgets are being redirected to AI, and the hosts float that canceled OpenAI deals could be equity-accretive if capacity re-contracts on the open market.
* Memory inflation (gigawatt DC cost maybe doubled) is the live constraint on Nvidia: if hyperscaler CapEx does not re-rate another 30–40%, chip budgets get crowded out even if token demand stays strong; TSMC’s $60B CapEx year still screens cheap net of Taiwan political risk.
* Healthcare: first FDA approval of a cancer treatment gated on an MRD (molecular residual disease) blood test (Roche/Genentech, bladder) validates the MRD-supplier thesis; UNH expected to show margin bounce on high-20s/low-30s premium hikes; BioNTech preferred over Moderna on cash discipline; Vertex’s non-opioid pain drug is inflecting as PBM formulary frictions ease; Harrow’s Q1 CVS co-pay buy-down error (negative revenue on formulary patients) is the near-term watch item.
Show Notes
[00:00:00] Intro & Welcome Mike opens Telltales; grab this week’s Cash Flow Memo at telltales.us.
[00:00:26] Exhibits A–C: Deficit, Hormuz & Oil Structure Hunt frames a multi-week Hormuz stalemate as closer-to-$80 crude with wider backwardation, producers still deciding off the 2027 strip; Exhibit A deficit runs roughly flat YoY through May, and any eventual sovereign-credit discipline will hit healthcare first.
[00:04:34] Where Is the Value? Hyperscalers on Page One Mike and Jason make the case for Amazon, Microsoft (~20x), and Google (~30x) as infrastructure bets: CapEx is optional, replacement cost of installed data centers is high, and OpenAI lease stress only reinforces that tokens-and-capacity — not the model layer — is where value accrues. Amazon’s Trainium and hosting playbook get special attention.
[00:08:24] Oracle: Cheap or Value Trap? Near a 52-week low with ~$110B net debt and heavy OpenAI-linked CapEx, Oracle draws a Charter-style leverage caution; IBM’s mainframe weakness is read as AI budget cannibalization of legacy software, and the hosts float that canceled OpenAI deals could re-rate capacity more cleanly.
[00:11:07] Nvidia, TSMC, Micron & the Memory Tax Nvidia and TSMC still screen as cheap on the memo; Jason’s live risk is memory cost doubling the price of a gigawatt of data center, crowding chip orders if hyperscaler CapEx doesn’t re-rate another 30–40%.
[00:12:34] Meta, Netflix & Content Share Meta’s cash-flow machine is hard to own without trusting Zuck’s CapEx (well above maintenance for the ad AI flywheel); Netflix at ~$73 looks like a value trap as market-share fears and content mix (Paramount improving) pressure the stock after walking away from Warner.
[00:15:43] Healthcare: MRD Approval, UNH Margins, Lilly & Cash-Rich Biotechs First FDA approval of a treatment administered off an MRD molecular test (Roche/Genentech, bladder cancer) validates the residual-disease thesis; UNH expected to print a margin bounce on high-20s/low-30s premium hikes; Lilly stays expensive for a reason; BioNTech preferred to Moderna on post-COVID cash discipline.
[00:21:29] Vertex Pipeline & Harrow/CVS Fix Vertex: kidney PDUFA path, non-opioid pain drug prescription data inflecting as PBM formulary issues ease, and a type-1 diabetes stem-cell program advancing; Harrow’s Q1 CVS co-pay buy-down created negative revenue on formulary patients — corrected, but Q2 commentary is the tell.
[00:24:54] Next Week & Close Hunt tees up page-20-and-back value hunting for next week; World Cup final Sunday in New Jersey; back in seven days.
Get the full Cash Flow Memo with updated financials on ~80 companies at telltales.us — new episodes every week.
Cashtags
$AMZN $BNTX $BRK.B $BWA $CHTR $CVS $GOOGL $HROW $HYNX $IROC $JPM $KO $LLY $META $MRNA $MSFT $MU $NFLX $NVDA $ORCL $PFE $PZG $TSM $UBER $UNH $VRTX
This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com
